DE60012517D1 - Methoden zur behandlung von diabetes - Google Patents
Methoden zur behandlung von diabetesInfo
- Publication number
- DE60012517D1 DE60012517D1 DE60012517T DE60012517T DE60012517D1 DE 60012517 D1 DE60012517 D1 DE 60012517D1 DE 60012517 T DE60012517 T DE 60012517T DE 60012517 T DE60012517 T DE 60012517T DE 60012517 D1 DE60012517 D1 DE 60012517D1
- Authority
- DE
- Germany
- Prior art keywords
- methods
- type
- diabetes
- symptoms
- treating diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 abstract 3
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 abstract 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 abstract 2
- 206010022491 Insulin resistant diabetes Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/326,189 US6040292A (en) | 1999-06-04 | 1999-06-04 | Methods for treating diabetes |
US326189 | 1999-06-04 | ||
PCT/US2000/014163 WO2000074710A2 (en) | 1999-06-04 | 2000-05-23 | Methods for treating diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60012517D1 true DE60012517D1 (de) | 2004-09-02 |
DE60012517T2 DE60012517T2 (de) | 2005-08-04 |
Family
ID=23271175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60012517T Expired - Lifetime DE60012517T2 (de) | 1999-06-04 | 2000-05-23 | Methoden zur behandlung von diabetes |
Country Status (16)
Country | Link |
---|---|
US (1) | US6040292A (de) |
EP (1) | EP1183042B1 (de) |
JP (1) | JP2003501397A (de) |
KR (1) | KR100694737B1 (de) |
CN (1) | CN1235637C (de) |
AT (1) | ATE271880T1 (de) |
AU (1) | AU780400B2 (de) |
CA (1) | CA2373281C (de) |
DE (1) | DE60012517T2 (de) |
ES (1) | ES2222208T3 (de) |
HK (1) | HK1044895A1 (de) |
IL (1) | IL146868A0 (de) |
MX (1) | MXPA01013384A (de) |
NO (1) | NO324117B1 (de) |
WO (1) | WO2000074710A2 (de) |
ZA (1) | ZA200110408B (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
KR100864120B1 (ko) * | 2000-07-03 | 2008-10-16 | 브리스톨-마이어스스퀴브컴파니 | 가용성 ctla4 분자를 사용한 류마티스성 질환의 치료법 |
CA2422625A1 (en) * | 2000-09-19 | 2002-03-28 | Bioexpertise, Llc | Method for use of igf-binding protein for selective sensitization of target cells in vivo |
US20040077679A1 (en) * | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
CN102860428A (zh) * | 2004-12-30 | 2013-01-09 | 希尔氏宠物营养品公司 | 用于猫消费的组合物 |
EP2148695B1 (de) * | 2007-04-18 | 2014-10-15 | Premacure AB | Verfahren und produkt zur behandlung und/oder vorbeugung von komplikationen in zusammenhang mit frühgeburten |
EP2352514A4 (de) * | 2008-10-29 | 2012-07-25 | Univ Rockefeller | Verfahren und kits zur krankheitsbehandlung durch verabreichung des einen insulinähnlichen wachstumsfaktor bindenden proteins 2 |
EP2413967A1 (de) | 2009-04-01 | 2012-02-08 | F. Hoffmann-La Roche AG | Behandlung von insulinresistenten erkrankungen |
US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
WO2012024161A1 (en) * | 2010-08-16 | 2012-02-23 | Allergan, Inc. | Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5200509A (en) * | 1987-04-06 | 1993-04-06 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides |
US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
GB8920381D0 (en) * | 1989-09-08 | 1989-10-25 | Greater Glasgow Health Board | Treatment of insulin-resistant diabetes |
SE9201573D0 (sv) * | 1992-05-19 | 1992-05-19 | Kabi Pharmacia Ab | Use of igf-1 |
GB9217696D0 (en) * | 1992-08-20 | 1992-09-30 | Agricultural & Food Res | Use of specific binding molecules |
US5407913A (en) * | 1992-12-03 | 1995-04-18 | Celtrix Pharmaceuticals, Inc. | Method and composition for systemic treatment of tissue injury |
EP0642350A4 (de) * | 1993-01-25 | 1995-06-28 | Beth Israel Hospital | Methode zur modifizierung, diagnose und dem aufspüren von igf-1 sensitiven zellbarriereeigenschaften. |
US5563046A (en) * | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
ATE190499T1 (de) * | 1993-08-03 | 2000-04-15 | Celtrix Pharma | Methode zur behandlung von reproduktionserkrankungen |
WO1995008567A1 (en) * | 1993-09-20 | 1995-03-30 | Celtrix Pharmaceuticals, Inc. | Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf |
JPH09509140A (ja) * | 1993-11-15 | 1997-09-16 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | 神経学的障害の治療方法 |
WO1995013824A1 (en) * | 1993-11-15 | 1995-05-26 | Celtrix Pharmaceuticals, Inc. | Method of treating renal disease by administering igf-i and igfbp-3 |
AU713275B2 (en) * | 1994-07-20 | 1999-11-25 | Celtrix Pharmaceuticals, Inc. | IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
-
1999
- 1999-06-04 US US09/326,189 patent/US6040292A/en not_active Expired - Lifetime
-
2000
- 2000-05-23 AU AU50411/00A patent/AU780400B2/en not_active Ceased
- 2000-05-23 DE DE60012517T patent/DE60012517T2/de not_active Expired - Lifetime
- 2000-05-23 JP JP2001501244A patent/JP2003501397A/ja active Pending
- 2000-05-23 MX MXPA01013384A patent/MXPA01013384A/es active IP Right Grant
- 2000-05-23 IL IL14686800A patent/IL146868A0/xx not_active IP Right Cessation
- 2000-05-23 CA CA002373281A patent/CA2373281C/en not_active Expired - Fee Related
- 2000-05-23 WO PCT/US2000/014163 patent/WO2000074710A2/en active IP Right Grant
- 2000-05-23 EP EP00932729A patent/EP1183042B1/de not_active Expired - Lifetime
- 2000-05-23 AT AT00932729T patent/ATE271880T1/de active
- 2000-05-23 CN CNB008112649A patent/CN1235637C/zh not_active Expired - Fee Related
- 2000-05-23 ES ES00932729T patent/ES2222208T3/es not_active Expired - Lifetime
- 2000-05-23 KR KR1020017015628A patent/KR100694737B1/ko not_active IP Right Cessation
-
2001
- 2001-12-04 NO NO20015932A patent/NO324117B1/no not_active IP Right Cessation
- 2001-12-19 ZA ZA200110408A patent/ZA200110408B/xx unknown
-
2002
- 2002-09-02 HK HK02106479A patent/HK1044895A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1044895A1 (en) | 2002-11-08 |
WO2000074710A3 (en) | 2001-06-28 |
WO2000074710A2 (en) | 2000-12-14 |
NO20015932L (no) | 2002-01-31 |
AU780400B2 (en) | 2005-03-17 |
IL146868A0 (en) | 2002-08-14 |
ES2222208T3 (es) | 2005-02-01 |
ZA200110408B (en) | 2003-03-19 |
CA2373281C (en) | 2010-01-12 |
CN1235637C (zh) | 2006-01-11 |
KR20020020723A (ko) | 2002-03-15 |
MXPA01013384A (es) | 2003-09-04 |
EP1183042B1 (de) | 2004-07-28 |
AU5041100A (en) | 2000-12-28 |
DE60012517T2 (de) | 2005-08-04 |
JP2003501397A (ja) | 2003-01-14 |
NO20015932D0 (no) | 2001-12-04 |
EP1183042A2 (de) | 2002-03-06 |
CA2373281A1 (en) | 2000-12-14 |
CN1387440A (zh) | 2002-12-25 |
NO324117B1 (no) | 2007-08-27 |
KR100694737B1 (ko) | 2007-03-14 |
US6040292A (en) | 2000-03-21 |
ATE271880T1 (de) | 2004-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60012517D1 (de) | Methoden zur behandlung von diabetes | |
ATE503490T1 (de) | Monodisperse mischungen und verfahren zur behandlung von diabetes | |
EA200300026A1 (ru) | Аналоги глюкагоноподобного пептида-1 | |
ATE482717T1 (de) | Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten | |
DE69521796T2 (de) | Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes | |
DK0915910T3 (da) | Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse | |
MXPA04001525A (es) | Analogos de peptido -1 similar al glucagon. | |
ATE462427T1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
BR0308904A (pt) | Método de tratamento de gastroparesia, e, uso de um composto de glp-1 | |
ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
NO940180D0 (no) | Anvendelse av IGF-I | |
DE59308848D1 (de) | Anwendung von urodilatin bei lungen- und bronchialerkrankungen | |
DE69924979D1 (de) | Behandlung von chronischen schmerzen | |
ATE262362T1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
DE60034110D1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
DE60033569D1 (de) | Neue verwendung von prodigiosin zur behandlung von diabetes mellitus | |
DE69905489D1 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
SE9303068D0 (sv) | New use | |
DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
GB9818650D0 (en) | Therapeutic compounds and methods of making and using the same | |
UA32295A (uk) | Спосіб лікування порушень фертильності у хворих на цукровий діабет | |
UA32255A (uk) | Спосіб лікування цукрового діабету | |
GEP19991688B (en) | Method for Treatment of Diabetes Mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |